Skip to main content

Resmed Value Stock - Dividend - Research Selection

Resmed

ISIN: US7611521078 , WKN: 895878

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


What You Need to Know Ahead of ResMed's Earnings Release

2026-01-05
ResMed will release its second-quarter earnings soon, and analysts anticipate a low double-digit bottom-line growth.

Here's What ResMed's (NYSE:RMD) Strong Returns On Capital Mean

2026-01-01
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...

Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes"

2025-12-30
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?

2025-12-30
Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.

Buy These 5 Low-Leverage Stocks Amid a Reversal of Santa Claus Rally

2025-12-30
A stalled Santa Claus rally has investors rotating to stability, spotlighting low-leverage names like Resmed that may hold up better amid tech-led volatility.

3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium

2025-12-30
Rising HSA limits and higher Medicare premiums in 2026 could lift demand for chronic care devices from DexCom, ResMed and Masimo.

1 Cash-Heavy Stock to Consider Right Now and 2 We Avoid

2025-12-29
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

1 Cash-Producing Stock Worth Your Attention and 2 We Brush Off

2025-12-22
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak competitive positioning.

Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

2025-12-18
SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, beginning at approximately 10:30 a.m. (Pacific Standard Time) in San Francisco, CA. More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://investor.resm

Stifel Maintains ResMed (RMD) Hold Recommendation

2025-12-18